Arbutus Biopharma Corporation

Arbutus Biopharma Corporation is a biopharmaceutical company specializing in the development of novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses. The company's product pipeline includes AB-729, a proprietary RNA interference product candidate targeting hepatocytes to inhibit viral replication, AB-836, an oral capsid inhibitor suppressing HBV DNA replication, and other research and development programs such as AB-161, an oral HBV RNA destabilizer, and AB-101, an oral PD-L1 inhibitor. Arbutus Biopharma Corporation also has strategic alliances, licensing, and research collaboration agreements with various pharmaceutical companies to advance its product portfolio.

Products

• AB-729 (RNA interference product)

• AB-836 (oral capsid inhibitor)

• AB-161 (oral HBV RNA destabilizer)

• AB-101 (oral PD-L1 inhibitor)